Dapagliflozin for heart recovery after atrial septal defect closure
Part of Genetic & congenital, Heart & circulation clinical trials.
This trial tests whether a medicine called dapagliflozin (usually used for diabetes or heart failure) helps the right side of the heart recover better after a procedure to close a hole in the heart (atrial septal defect). It may improve your heart's function and reduce strain after the closure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of hole in the heart called an atrial septal defect that can be closed with a catheter-based procedure.
- Your heart rhythm is normal (no atrial fibrillation or other arrhythmias).
- You do not have other major heart defects, severe pulmonary hypertension, or significant heart valve disease.
- Your kidney function is not severely reduced (eGFR at least 30).
- You are not diabetic on insulin or have a history of ketoacidosis, and you have no active genital or urinary infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial tests if the medicine dapagliflozin (commonly used for diabetes and heart failure) can help prevent atrial fibrillation from coming back after a catheter ablation. By taking this medicine after your first ablation, researchers hope to reduce the chance of the irregular heartbeat returning.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
Hear when a new ASD2(Secundum Atrial Septal Defect) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.